67 phenotypes from multigenic genotypes

Allelic Composition Genetic Background	Annotated Term	Reference
Cdk2tm1Kald/Cdk2tm1Kald Cdk4tm1Kiyo/Cdk4tm1Kiyo involves: 129S1/Sv * C57BL/6	abnormal cardiac output	J:108720
	abnormal cell cycle	J:108720
	abnormal erythrocyte morphology	J:108720
	abnormal eye morphology	J:108720
	abnormal fetal cardiomyocyte proliferation	J:108720
	abnormal heart valve morphology	J:108720
	abnormal hematopoietic stem cell morphology	J:108720
	abnormal liver morphology	J:108720
	decreased cell proliferation	J:108720
	decreased embryo size	J:108720
	edema	J:108720
	hemorrhage	J:108720
	increased heart atrium size	J:108720
	lethality throughout fetal growth and development, incomplete penetrance	J:108720
	myocardial fiber disarray	J:108720
	pallor	J:108720
	small heart	J:108720
	thin ventricular wall	J:108720
	ventricular septal defect	J:108720
Cdk2tm1Kald/Cdk2tm1Kald Cdk4tm1Kiyo/Cdk4tm1Kiyo Cdkn1btm1Ako/Cdkn1btm1Ako involves: 129S1/Sv * C57BL/6	decreased cell proliferation	J:108720
	lethality throughout fetal growth and development, complete penetrance	J:108720
Cdk2tm1Sgo/Cdk2+ Cdk4tm2.1Bbd/Cdk4+ involves: 129S1/Sv * 129X1/SvJ * BALB/cJ * C57BL/6 * SJL	abnormal embryo development	J:125217
Cdk2tm1Sgo/Cdk2tm1Sgo Cdk4tm1Bbd/Cdk4tm1Bbd Cdk6tm1Bbd/Cdk6tm1Bbd involves: 129S1/Sv * 129X1/SvJ * C57BL/6	abnormal common myeloid progenitor cell morphology	J:124678
	decreased cell proliferation	J:124678
	decreased embryo size	J:124678
	decreased myocardial fiber number	J:124678
	embryonic lethality during organogenesis, incomplete penetrance	J:124678
	lethality throughout fetal growth and development, complete penetrance	J:124678
	liver hypoplasia	J:124678
	thin ventricular wall	J:124678
Cdk2tm1Sgo/Cdk2tm1Sgo Cdk4tm2.1Bbd/Cdk4tm2.1Bbd involves: 129S1/Sv * 129X1/SvJ * BALB/cJ * C57BL/6 * SJL	abnormal cell cycle	J:125217
	abnormal definitive hematopoiesis	J:125217
	abnormal fetal cardiomyocyte proliferation	J:125217
	abnormal liver physiology	J:125217
	congestive heart failure	J:125217
	decreased body weight	J:125217
	decreased erythrocyte cell number	J:125217
	decreased fibroblast proliferation	J:125217
	increased myocardial fiber size	J:125217
	liver hypoplasia	J:125217
	neonatal lethality, complete penetrance	J:125217
	thin ventricular wall	J:125217
Cdk2tm2Sgo/Cdk2tm2Sgo Cdk4tm2.1Bbd/Cdk4tm2.1Bbd Polr2atm1(cre/ERT2)Bbd/? involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL	decreased body size	J:125217
	normal hematopoietic system phenotype	J:125217
	increased susceptibility to autoimmune diabetes	J:125217
	normal liver/biliary system phenotype	J:125217
Cdk4tm1.1Bbd/Cdk4+ Tg(Mt1-Hgf)#Lmb/0 B6.Cg-Cdk4tm1.1Bbd Tg(Mt1-Hgf)#Lmb	abnormal axillary lymph node morphology	J:111992
	abnormal inguinal lymph node morphology	J:111992
	decreased tumor growth/size	J:111992
	enlarged axillary lymph nodes	J:111992
	enlarged inguinal lymph nodes	J:111992
	increased incidence of tumors by chemical induction	J:111992
	increased metastatic potential	J:111992
Cdk4tm1.1Bbd/Cdk4+ Krastm1Bbd/Kras+ Tg(CMV-cre)1Cgn/? involves: 129S1/Sv * 129X1/SvJ * BALB/cJ * C57BL/6	abnormal pancreatic duct morphology	J:86101
	increased hemangiosarcoma incidence	J:86101
	increased lung adenoma incidence	J:86101
	increased papilloma incidence	J:86101
	increased pituitary adenoma incidence	J:86101
	increased sarcoma incidence	J:86101
Cdk4tm1.1Bbd/Cdk4tm1.1Bbd Krt14tm1(cre)Wbm/Krt14+ Pard3tm1Shoh/Pard3tm1Shoh Tg(Mt1-Hgf)#Lmb/0 involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6J	increased incidence of tumors by chemical induction	J:240961
	increased metastatic potential	J:240961
	increased tumor growth/size	J:240961
Cdk4tm1.1Bbd/Cdk4tm1.1Bbd Tg(Mt1-Hgf)#Lmb/0 B6.Cg-Cdk4tm1.1Bbd Tg(Mt1-Hgf)#Lmb	abnormal axillary lymph node morphology	J:111992
	abnormal inguinal lymph node morphology	J:111992
	enlarged axillary lymph nodes	J:111992
	enlarged inguinal lymph nodes	J:111992
	increased cutaneous melanoma incidence	J:111992
	increased incidence of tumors by chemical induction	J:111992
	increased metastatic potential	J:111992
	increased skin tumor incidence	J:111992
	increased tumor growth/size	J:111992
Cdk4tm1.1Bbd/Cdk4tm1.1Bbd Tg(Tyr-NRAS*Q61K)1Bee/0 FVB.Cg-Cdk4tm1.1Bbd Tg(Tyr-NRAS*Q61K)1Bee	abnormal melanocyte proliferation	J:222847
	increased cutaneous melanoma incidence	J:222847
	increased incidence of tumors by UV-induction	J:222847
	increased melanocyte number	J:222847
	skin lesions	J:222847
Cdk4tm1Bbd/Cdk4tm1Bbd Cdk6tm1Bbd/Cdk6tm1Bbd involves: 129S1/Sv * 129X1/SvJ * CD-1 * ICR	abnormal erythrocyte morphology	J:92529
	decreased embryo size	J:92529
	decreased erythrocyte cell number	J:92529
	decreased hematopoietic stem cell number	J:92529
	extramedullary hematopoiesis	J:92529
	lethality throughout fetal growth and development, incomplete penetrance	J:92529
	liver hypoplasia	J:92529
	neonatal lethality, complete penetrance	J:92529
Cdk4tm1Kiyo/Cdk4+ Lin9tm1Orc/Lin9+ involves: 129S1/Sv	abnormal cell cycle	J:111333
	decreased susceptibility to autoimmune diabetes	J:111333
Cdk4tm1Kiyo/Cdk4tm1Kiyo Lin9tm1Orc/Lin9tm1Orc involves: 129S1/Sv	abnormal cell cycle	J:111333
	adenohypophysis hypoplasia	J:111333
	decreased body weight	J:111333
	female infertility	J:111333
	male infertility	J:111333
Cdk4tm2.1Bbd/Cdk4tm2.1Bbd Krastm1Bbd/Krastm2Bbd Polr2atm1(cre/ERT2)Bbd/Polr2atm1(cre/ERT2)Bbd involves: 129S1/Sv * 129X1/SvJ	decreased cell proliferation	J:161780
	decreased tumor growth/size	J:161780
	early cellular replicative senescence	J:161780
	increased adenocarcinoma incidence	J:161780
Cdk4tm2.2Bbd/Cdk4tm2.1Bbd Krastm1Bbd/Krastm2Bbd Polr2atm1(cre/ERT2)Bbd/Polr2atm1(cre/ERT2)Bbd involves: 129S1/Sv * 129X1/SvJ	decreased cell proliferation	J:161780
	decreased tumor growth/size	J:161780
	decreased tumor incidence	J:161780
	early cellular replicative senescence	J:161780
	increased tumor incidence	J:161780
Cdk4tm2.2Bbd/Cdk4tm2.2Bbd Krastm1Bbd/Krastm1Bbd Polr2atm1(cre/ERT2)Bbd/Polr2atm1(cre/ERT2)Bbd involves: 129S1/Sv * 129X1/SvJ	decreased tumor incidence	J:161780